Evidence map›Paper›PMID 33868241›Full record

ArticleFrontiers in immunology2021

T Cell Receptor Repertoires Acquired

Scott Christley, Jared Ostmeyer, Lisa Quirk, Wei Zhang, Bradley Sirak, Anna R Giuliano, Song Zhang, Nancy Monson, Jasmin Tiro, Elena Lucas and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Machine learning in AIRR diagnostics: Advances and applications.Immunoinformatics (Amsterdam, Netherlands) · 2025
    Article
  4. Preparing Allergists to Practice in 2050 Using Artificial Intelligence.The journal of allergy and clinical immunology. In practice · 2025
    Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Scott ChristleyDepartment of Population and Data Sciences, UT Southwestern Medical Center, Dallas, TX, United States.
Jared OstmeyerDepartment of Population and Data Sciences, UT Southwestern Medical Center, Dallas, TX, United States.
Lisa QuirkDepartment of Population and Data Sciences, UT Southwestern Medical Center, Dallas, TX, United States.
Wei ZhangDepartment of Neurology and Neurotherapeutics, Department of Immunology, UT Southwestern Medical Center, Dallas, TX, United States.
Bradley SirakCenter for Immunization and Infection Research, Moffitt Cancer Center, Tampa, FL, United States.
Anna R GiulianoCenter for Immunization and Infection Research, Moffitt Cancer Center, Tampa, FL, United States.
Song ZhangDepartment of Population and Data Sciences, UT Southwestern Medical Center, Dallas, TX, United States.
Nancy MonsonDepartment of Neurology and Neurotherapeutics, Department of Immunology, UT Southwestern Medical Center, Dallas, TX, United States.
Jasmin TiroDepartment of Population and Data Sciences, UT Southwestern Medical Center, Dallas, TX, United States.
Elena LucasDepartment of Pathology, UT Southwestern Medical Center, Dallas, TX, United States.
Lindsay G CowellDepartment of Population and Data Sciences, UT Southwestern Medical Center, Dallas, TX, United States.
Southwestern Medical CenterMoffitt Cancer Center · USThe University of Texas Southwestern Medical Center · USSouthwestern Medical Center · US

Funding

UT Southwestern Center for Translational MedicineUL1TR003163 · NCATS · UT SOUTHWESTERN MEDICAL CENTER · PI TOTO, ROBERT DANIEL · 2021 to 2025
$39.3M
NCATS NIH HHS UL1 TR003163
6 · The paper itself

Abstract

Cervical cancer is the fourth most common cancer and fourth leading cause of cancer death among women worldwide. In low Human Development Index settings, it ranks second. Screening and surveillance involve the cytology-based Papanicolaou (Pap) test and testing for high-risk human papillomavirus (hrHPV). The Pap test has low sensitivity to detect precursor lesions, while a single hrHPV test cannot distinguish a persistent infection from one that the immune system will naturally clear. Furthermore, among women who are hrHPV-positive and progress to high-grade cervical lesions, testing cannot identify the ~20% who would progress to cancer if not treated. Thus, reliable detection and treatment of cancers and precancers requires routine screening followed by frequent surveillance among those with past abnormal or positive results. The consequence is overtreatment, with its associated risks and complications, in screened populations and an increased risk of cancer in under-screened populations. Methods to improve cervical cancer risk assessment, particularly assays to predict regression of precursor lesions or clearance of hrHPV infection, would benefit both populations. Here we show that women who have lower risk results on follow-up testing relative to index testing have evidence of enhanced T cell clonal expansion in the index cervical cytology sample compared to women who persist with higher risk results from index to follow-up. We further show that a machine learning classifier based on the index sample T cells predicts this transition to lower risk with 95% accuracy (19/20) by leave-one-out cross-validation. Using T cell receptor deep sequencing and machine learning, we identified a biophysicochemical motif in the complementarity-determining region 3 of T cell receptor β chains whose presence predicts this transition. While these results must still be tested on an independent cohort in a prospective study, they suggest that this approach could improve cervical cancer screening by helping distinguish women likely to spontaneously regress from those at elevated risk of progression to cancer. The advancement of such a strategy could reduce surveillance frequency and overtreatment in screened populations and improve the delivery of screening to under-screened populations.

Indexed as

Early Detection of CancerGenes, T-Cell Receptor betaPapanicolaou TestVaginal SmearsAdultAlphapapillomavirusComplementarity Determining RegionsFemaleGene Expression ProfilingHigh-Throughput Nucleotide SequencingHuman Papillomavirus DNA TestsHumansMachine LearningMiddle AgedPapillomavirus InfectionsPrecancerous ConditionsComplementarity Determining Regionscervical cancer screeningcervical cancer surveillanceimmune repertoiremachine learningregression biomarker

Identifiers

PMID33868241
PMCPMC8050337
OpenAlexW3151280242

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.